title: [Osteoporosis and pharmaceutical care].
abstract: The increasing prevalence of osteoporosis is causing a substantial health burden. Compliance and adherence to osteoporosis management are of high priority, having a significant effect on the cost effectiveness of therapy. In this study, we aimed to summarize the literature on patient compliance in osteoporosis. Our findings indicate that 60% of the patients have some medication related problem, in particular, it is difficult to influence the patients to play an active role in their disease management and to keep a high level of persistence. Pharmaceutical care could help to reach optimal cooperation between patients and the heath care professional, as one of its main objective is to improve the rate of patient adherence in long-term drug therapy.
authors.affiliation: Semmelweis Egyetem, GYTK Egyetemi Gyógyszertár Gyógyszerügyi Szervezési Intézet H-1092 Budapest, Hőgyes Endre u. 7-9.
authors.forename: Kinga
authors.initials: K
authors.lastname: Kövér
authors.forename: Agnes
authors.initials: A
authors.lastname: Mészáros
mesh_terms: D000284:Administration, Oral; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000191:economics; D003362:Cost-Benefit Analysis; D003720:Densitometry; D004164:Diphosphonates / Q000008:administration & dosage; D004967:Estrogens / Q000008:administration & dosage; D006801:Humans; D006814:Hungary / Q000453:epidemiology; D007262:Infusions, Intravenous; D008487:Medical History Taking; D055118:Medication Adherence / Q000523:psychology; D010024:Osteoporosis / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy; D010281:Parathyroid Hormone / Q000008:administration & dosage; D010593:Pharmaceutical Services / Q000592:standards / Q000639:trends; D015995:Prevalence; D011374:Progesterone / Q000008:administration & dosage; D053245:RANK Ligand / Q000276:immunology; D011994:Recombinant Proteins / Q000008:administration & dosage; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage; D012646:Self Administration; D013997:Time Factors; D016903:Drug Monitoring
chemical_list: D000911:Antibodies, Monoclonal; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D004967:Estrogens; D010281:Parathyroid Hormone; D053245:RANK Ligand; D011994:Recombinant Proteins; D020845:Selective Estrogen Receptor Modulators; C505688:TNFSF11 protein, human; D011374:Progesterone